Description

Description

Diajard-M XR 25/1000mg is a prescription medicine manufactured by Highnoon Laboratories, combining Empagliflozin and Metformin in an extended-release tablet form. This fixed-dose combination brings together two complementary approaches to blood sugar management, with the Metformin component formulated to release gradually over time rather than all at once. Empagliflozin belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, working by limiting glucose reabsorption in the kidneys and encouraging its excretion through urine. This strength represents the highest Empagliflozin dose available within the Diajard-M XR range, paired with the higher extended-release Metformin strength, and is generally reserved for patients whose treatment plan has been specifically assessed by a physician as requiring the upper strength of both components. Metformin works mainly by reducing glucose production in the liver while improving the body’s response to insulin, with its gradual release profile intended to help reduce the gastrointestinal discomfort that can accompany immediate-release Metformin. Each pack of Diajard-M XR 25/1000mg contains 14 tablets, produced under the quality standards maintained by Highnoon Laboratories.

Ingredients

Diajard-M XR 25/1000mg contains two active ingredients: Empagliflozin at a strength of 25 milligrams and Metformin Hydrochloride, in extended-release form, at a strength of 1000 milligrams per tablet. The formulation also includes inactive excipients such as extended-release matrix-forming agents, binding materials, and film-coating components, which work together to control the gradual release of Metformin and support the tablet’s structural integrity. These excipients carry no therapeutic effect on their own but are essential to the tablet’s release mechanism and overall stability.

Dosage Form

Diajard-M XR 25/1000mg is available as an oral extended-release film-coated tablet. Each pack contains 14 tablets, providing a supply suited to a once-daily combination treatment schedule as directed by a physician. Owing to its extended-release design, the tablet should be swallowed whole and must not be crushed, split, or chewed, as this could interfere with the controlled release mechanism.

Uses

Diajard-M XR 25/1000mg is used to help improve blood sugar control in adults with type 2 diabetes mellitus, particularly where a physician determines that the highest Empagliflozin strength alongside extended-release Metformin is appropriate for the patient’s individual treatment needs. It is generally used alongside dietary changes and regular physical activity as part of a broader diabetes management plan, typically for patients who have already been established on lower combination strengths and require further intensification. This medicine is not intended for individuals with type 1 diabetes or for the management of diabetic ketoacidosis. The suitability of this specific strength for any individual patient should always be confirmed through proper medical assessment.

How to Use

Diajard-M XR 25/1000mg should be taken exactly as directed by a prescribing physician, typically once daily with the evening meal, which may help support tolerability and the intended extended-release action, particularly given the higher strengths of both components. The tablet must be swallowed whole with a glass of water and should never be crushed, split, or chewed, as doing so could disrupt the extended-release formulation and alter how the medicine is absorbed. Patients should continue to follow any dietary and lifestyle recommendations provided by their doctor and must never modify the dosage without medical advice. Regular monitoring of blood sugar levels, kidney function, and overall hydration status is typically recommended throughout treatment, given the higher combined strength.

Side Effects

Diajard-M XR 25/1000mg may cause side effects in some individuals, although not everyone will experience them. Commonly reported effects include gastrointestinal symptoms such as mild nausea, diarrhea, or stomach discomfort, which may be more noticeable at this higher Metformin strength despite the extended-release formulation, particularly when treatment is first started. Effects associated with the highest-strength Empagliflozin component, such as urinary tract infections, genital yeast infections, and increased urination, may also occur, and some patients may notice these effects more than with lower Empagliflozin doses. Mild dizziness or symptoms related to dehydration may also be experienced. A rare but serious risk linked to Metformin-containing medicines is lactic acidosis, which can present as unusual muscle pain, difficulty breathing, abdominal discomfort, or unexplained fatigue, requiring immediate medical attention if suspected. Patients with kidney or liver concerns, a history of heavy alcohol use, or those undergoing procedures involving contrast dye should inform their doctor before starting this medicine, and closer monitoring may be advised given the higher combined strength.

Pregnancy & Breastfeeding

The use of Diajard-M XR 25/1000mg during pregnancy or breastfeeding should only occur under the specific direction of a qualified healthcare provider, as its suitability depends on individual clinical circumstances. Women who are pregnant, planning pregnancy, or breastfeeding should discuss their situation with their doctor before starting or continuing this combination medicine.

Storage Instructions

Diajard-M XR 25/1000mg tablets should be stored in a cool, dry place away from direct sunlight and excess humidity, at the room temperature indicated on the packaging. Tablets should remain in their original blister pack until they are ready to be used, helping protect them from moisture and light exposure. Keep out of reach of children and pets, and avoid storage in areas with fluctuating temperatures such as bathrooms or vehicles.

FAQS

Q: Is Diajard-M XR 25/1000mg the strongest combination available?
Yes, it combines the highest Empagliflozin dose with the higher extended-release Metformin dose, making it the strongest option in the Diajard-M XR range.

Q: Can Diajard-M XR 25/1000mg tablets be split or crushed?
No, the tablet should always be swallowed whole, as splitting or crushing can interfere with its extended-release mechanism.

Q: Is this strength typically used as a starting dose?
It is generally not used as a first-choice starting dose and is more often prescribed after a patient has been assessed on lower combination strengths, as determined by a doctor.

Q: What monitoring is recommended at this strength?
Doctors often recommend closer monitoring of kidney function, hydration status, and blood sugar response at this higher combined strength compared to lower-dose options.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.